Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects

Cardiovascular Research

Volumn 61, Issue 4, 2004, Pages 806-816

  Vilahur, Gemma ^a   Baldellou, María Isabel ^a   Segalés, Estefania ^a   Salas, Eduardo ^b   Badimon, Lina ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Lacer SA   (Spain)

Author keywords

Nitric oxide; Pig; Platelets; Thrombosis

Indexed keywords

COLLAGEN; CYCLIC GMP; LA 810; NITRIC OXIDE DONOR; S NITROSOTHIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; EX VIVO STUDY; EXPERIMENTAL MODEL; FEMALE; HEART RATE; HEMODYNAMICS; HYPOTENSION; IN VITRO STUDY; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; STATISTICAL SIGNIFICANCE; SWINE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPOIESIS; THROMBOGENESIS; THROMBOGENICITY; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CORONARY DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; CYCLIC GMP; FEMALE; GLYCINE; MODELS, ANIMAL; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PLATELET AGGREGATION INHIBITORS; S-NITROSOTHIOLS; STRESS, MECHANICAL; SULFHYDRYL COMPOUNDS; SWINE;

EID: 1342302816     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.11.034     Document Type: Article

References (46)

1. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326:1992;242-250.
2. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 326:1992;310-318.
3. Badimon L., Chesebro J.H., Badimon J.J. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation. 86:1992;III74-III85.
4. Giles H., Smith R.E.A., Martin J.F. Platelet glycoprotein IIb/IIIa and size are increased in acute myocardial infarction. Eur. J. Clin. Invest. 24:1994;69-72.
5. Coller B.S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb. Haemost. 86:2001;427-443.
6. Quinn M.J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 106:2002;379-385.
7. Freedman J.E., Ting B., Hankin B., Loscalzo J., Keaney J.F. Jr., Vita J.A. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 98:1998;1481-1486.
8. Luscher T.F. Vascular protection: current possibilities and future perspectives. Int. J. Clin. Pract. Suppl. 117:2001;3-6.
9. Garthwaite J. Glutamat, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci. 14:1991;60-67.
10. Hibbs J.B. Sythesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumor and antimicrobial activity. Immunol. Res. 142:1991;565-569.
11. Moncada S. Nitric oxide. J. Hypertens. Suppl. 12:1994;S35-S39.
12. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
13. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 100:1997;350-356.
14. Singh R.J., Hogg N., Joseph J., Kalyanaraman B. Mechanism of nitric oxide release from S-nitrosothiols. J. Biol. Chem. 271:1996;18596-18603.
15. Ignarro L.J. Introduction and overview in nitric oxide: biology and pathobiology. Ignarro L.J. 2000;3-19 Academic Press, San Diego, CA (USA).
16. de Belder A.J., MacAllister R., Radomski M.W., Moncada S., Vallance P.J. Effects of S-nitrosoglutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc. Res. 28:1994;691-694.
17. Kaposzta Z., Baskerville P.A., Madge D., Fraser S., Martin J.F., Markus H.S. L-arginine and S-nitrosothiol reduce embolization in humans. Circulation. 103:2001;2371-2375.
18. Langford E.J., Brown A.S., Wainwright R.J., de Belder A.J., Thomas M.R., Smith R.E., et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet. 344:1994;1458-1460.
19. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;1540.
20. Collaborative overview of randomised trials of antiplatelet therapy: II. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;159-168.
21. Collaborative overview of randomised trials of antiplatelet therapy: III. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;235-246.
22. International patent number WO oo/44714. Intellectual property world organization, S-nitrosothiols as agents for the treatment of circulatory dysfunctions.
23. Badimon L., Turitto V., Rosemark J.A., Badimon J.J., Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of Indium 111-labeled platelets on collagen, subendothelium and expanded polytetrafluoroethylene. J. Lab. Clin. Med. 110:1987;706-718.
24. O'Rourke S.T., Folts J.D., Albretcht R.M. Studies on the inhibition of canine platelet aggregation by barbiturates. J. Lab. Clin. Med. 108:1986;206-212.
25. Badimon L., Badimon J.J. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J. Clin. Invest. 84:1989;1134-1144.
26. Bird R.B., Stewart W.E., Lightfoot E.N. Transport phenomena. 1960;Wiley, New York.
27. Galvez A., Badimon L., Badimon J.J., Fuster V. Electrical aggregometry in whole blood from humans, pigs and rabbit. Thromb. Haemost. 56:1986;128-136.
28. Radomski M.W., Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb. Res. 90:1983;383-389.
29. Royo T., Vidal M., Badimon L. Porcine platelet von Willebrand antigen II (vW AgII): inhibitory effect on collagen-induced aggregation and comparative distribution with human platelets. Thromb. Haemost. 80:1998;677-685.
30. Martinez-Gonzalez J., Berrozpe M., Varela O., Badimon L. Heterogeneity of smooth muscle cells in advanced human atherosclerotic plaques: intimal smooth muscle cells expressing a fibroblast surface protein are highly activated by platelet-released products. Eur. J. Clin. Invest. 31:2001;939-949.
31. Xiong Y., Westhead E.W., Slakey L.L. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem. J. 305:1995;627-633.
32. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
33. Richardson G., Benjamin N. Potential therapeutical uses for S-nitrosothiols. Clin. Sci. 102:2002;99-105.
34. Darblade B., Privat C., Caillaud D., Rami J., Arnal J.F. Clinical and biological investigation of NO. J. Soc. Biol. 194:2000;151-157.
35. Sterin-Borda L., Gomez R.M., Borda E. Role of nitric oxide/cyclic GMP in myocardial adenosine A1 receptor-inotropic response. Br. J. Pharmacol. 135:2002;444-450.
36. Ramsay B., Radomski M., de Belder A., Martin J.F., Lopez-Jaramillo P. Systemic effects of S-nitrosoglutathione in the humans following intravenous infusion. Br. J. Clin. Pharmacol. 40:1995;101-102.
37. Salas E., Langford E.J.J., Marrinan M.T., Martin J.F., Moncada S., de Belder A.J. S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo. Heart. 28:1998;691-694.
38. Langford E.J., Parfitt A., de Belder A.J., Marrinan M.T., Martin J.F. A study of platelet activation during human cardiopulmonary bypass and the effect of S-nitrosoglutathione. Thromb. Haemost. 78:1997;1516-1519.
39. Vodovotz Y., Waksman R., Cook J.A., Kim W.H., Chan R., Seabron R., et al. S-nitrosoglutathione reduces nonocclusive thrombosis rate following balloon overstretch injury and intracoronary irradiation of porcine coronary arteries. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1167-1174.
40. Megson I.L., Sogo N., Mazzei F.A., Butler A.R., Walton J.C., Webb D.J. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br. J. Pharmacol. 131:2000;1391-1398.
41. Salas E., Moro M.A., Askey S., Hodson H.F., Butler A.R., Radomski M.W., et al. Compartive pharmacology of analogues of S-nitroso-N-acetyl-DL- penicillamine on human platelets. Br. J. Pharmacol. 112:1994;1071-1076.
42. Maddox A.S., Burridge K. RhoA is required for cortical retraction and rigidity during mitotic cell rounding. J. Cell Biol. 160:2003;255-265.
43. Begum N., Sandu O.A., Duddy N. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways. Diabetes. 51:2002;2256-2263.
44. Bernassola F., Rossi A., Melino G. Regulation of transglutaminases by nitric oxide. Ann. N. Y. Acad. Sci. 887:1999;83-91.
45. Badimon J.J., Lettino M., Toschi V., Fuster V., Berrozpe M., Chesebro J.H., et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 99:1999;1780-1787.
46. Yang Y., Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation. 101:2000;2144-2148.